It's a wrap! Farewell 2 Martha @MarthaGrogan1, Murielle @RousselMurielle & Isabelle @i_lousada. 🙏 4 touring Australia & educating, advocating, empowering our whole community-Drs & patients alike. Happy Sad photo from our last Workshop in Adelaide 2day.

The absolute highlight of our Amyloidosis workshop. 91 year old Jackie with cardiac TTR amyloid on a clinical trial drove herself down to attend. Here is her with her Haematology advanced trainee granddaughter Elly. @simondjgibbs @OzAmyloidosis

Our concurrent East and West Coast Oz Amyloidosis Workshops have kicked off! Melbourne’s Workshop opened by @simondjgibbs & Perth’s by @sidiqi_hasib. Image from Melbourne’s Health Professional’s Workshop.

https://t.co/4zHMemXKtA

AAN AMYLOIDOSIS WORKSHOP 2023 Perth gets underway. Dr Bill Macdonald presenting on imaging in Amyloidosis. @OzAmyloidosis @simondjgibbs @PortiaSmallbone

Why artists make good Haematologists- nuclear chromatin is like paint. Take the Quiz to test your painting skills

Blast vs atypical lymphocyte: can a systematic approach solve the dilemma?

We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? https://t.co/AJ9S3VCXpV #lymsm @BloodAdvances @AdaptiveBiotech @BrownHeme

Finally, the manuscript for Part 2 CASSIOPEIA trial (Dara Maint. vs Obs.) is out!! Extremely glad that there was a 2𝒏𝒅 𝒓𝒂𝒏𝒅𝒐𝒎𝒊𝒛𝒂𝒕𝒊𝒐𝒏 instead of automatically continuing Dara Mx in Dara-VTD arm. My take on the results 🧵1/10 @TheLancet #mmsm https://t.co/fBlEnw0xFS

IMW 2021 ROUND-UP: DocWire News Guest Correspondent Manni Mohyuddin, MD (@ManniMD1), of the University of Utah, provides a thorough report of the top news emerging from the 2021 International #Myeloma Workshop. Don't miss it! #hematology #cancer #oncology

Just out: CAR-T therapy with cilta-cel shows excellent results in refractory myeloma. 97 patients 6 prior therapies Response rate: 97% sCR rate: 67% At 12-months Progression-free: 77% Survival: 89% Grade 3-4 toxicity CRS:4% Neuro: 9% @TheLancet https://t.co/tmi3C13WuJ

Short tweetorial on Renal Amyloidosis #onconephrology 1) Not all amyloidosis is AL

Happy weekend! Next Saturday, join us for our virtual Health Professionals Amyloidosis 2021 Workshop with Prof Morie Gertz @MorieGertz & Prof Claudio Rapezzi. Registrars & RNs can now register for free thx 2 our generous sponsors. Program & registration 👉 https://t.co/fmArf0bRwi

Great talk by @simondjgibbs at @ALLGtrials myeloma working group about unmet needs in AL amyloidosis and planned collaborative trials between IFM 🇫🇷 and @ALLGtrials 🇦🇺 @OzAmyloidosis

Dr Simon Gibbs returned to Australia from his time in London with a mission: to improve the diagnosis, treatment and supportive care for people diagnosed with amyloidosis.

Breaking News: lde-cel (Abecma; idecabtagene vicleucel), approved by FDA for multiple myeloma. This is the first CAR-T therapy for myeloma. Many patients have been waiting for this good news. @agarwalonc @BMS_Myeloma_US @bluebirdbio

It’s a landmark day for myeloma patients with first FDA approval of BCMA directed CAR-T therapy. Ide-cel (ABECMA) approved! #mmsm https://t.co/fwQLwGSRPK

1/ Our manuscript on use of stored stem cells in patients with myeloma undergoing stem cell transplant is out. - Overall, 7% patients used stored stem cells, including 2% for stem cell boost. - Relapsed patients: only 7.5% underwent 2nd transplant https://t.co/YonoCnNjP4

I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives. 1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

Our new paper on second infusions of CD19 CAR T-cells is finally out *in print* in @BloodJournal ! https://t.co/Ez9ozIaQvz Time for a little Tweetorial 😄 Please retweet for your CAR T-cell friends/aficionados 😉 [THREAD 🧵] 1/24 @fredhutch @RyanCassaday